London, United Kingdom

Cecile Voisset

This inventor holds 1 USPTO granted patent. Top assignee: Biomerieux, Inc.. Active years: 2009.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Cecile Voisset: Innovator in Autoimmune Disease Research

Introduction

Cecile Voisset is a prominent inventor based in London, GB. She has made significant contributions to the field of autoimmune disease research through her innovative work. Her dedication to advancing medical science is evident in her patented inventions.

Latest Patents

Cecile Voisset holds a patent for an "Endogenous nucleic acid fragment associated with an autoimmune disease, labeling method and reagent." This invention concerns an endogenic nucleic fragment, such as an isolated retrovirus, integrated into the human DNA genome. The fragment is characterized by comprising, or consisting of, at least part of the gag gene of an endogenetic retrovirus associated with autoimmune diseases or pregnancy pathologies. This part codes, directly and indirectly, for an expression product or the complement of the fragment. She has 1 patent to her name.

Career Highlights

Cecile Voisset is currently employed at bioMérieux, Inc., where she continues her research and development efforts. Her work focuses on understanding the complexities of autoimmune diseases and developing innovative solutions to address these health challenges.

Collaborations

Cecile has collaborated with notable colleagues, including Glaucia Paranhos-Baccala and Francois Mallet. These partnerships have enhanced her research and contributed to the advancement of knowledge in her field.

Conclusion

Cecile Voisset is a dedicated inventor whose work in autoimmune disease research has the potential to make a significant impact on medical science. Her innovative patent and collaborations reflect her commitment to improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…